Following the conclusion of the Phase A, the outcome of two parallel activities will be presented.
In the present experiments, cortisol concentrations were elevated in jet-lagged hamsters throughout the course of the treatment, with recovery seen near the conclusion of the phase shifting (Figure 4A).
The maximum tolerated dose for monotherapy was not reached at the conclusion of the phase 1 trials for any of the anti IGF-1R manti IGF-1R
Here's the key conclusion: The production phase of EVs proved substantially more environmentally intensive.
Conclusion: The stimulatory phase of gonadotropin-releasing hormone agonist therapy is associated with an increase in endometriosis-associated pain and a decrease in quality of life.
In conclusion, the present phase I trial showed that the combination of low-dose NGR-hTNF and standard-dose doxorubicin is feasible, safe, and well tolerated when administered to patients heavily pre-treated with chemotherapy, including anthracyclines.
In conclusion, the present phase II study reports a high rate of pCR in locally advanced HER2 overexpressing BC patients treated with a NC regimen excluding anthracyclines and combining trastuzumab and paclitaxel in a weekly schedule.
In conclusion, the present phase I II study determined the feasibility of the docetaxel ifosfamide combination, defined the MTD and demonstrated the encouraging activity of the regimen in phase II, thus warranting further randomised phase III comparisons to single-agent docetaxel or combinations of the latter with other active agents.
In conclusion, the current phase I study clearly demonstrates that the triplet combination of PLD plus PCX and GEM given every 2 weeks is a well-tolerated regimen, which merits further evaluation in phase II studies in patients with sensitive tumours such as breast, ovarian or head and neck cancer.
